Literature DB >> 11804742

Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma.

Tadashi Hanafusa1, Yasuhiro Yumoto, Kazuhiro Nouso, Harushige Nakatsukasa, Toru Onishi, Tatsuya Fujikawa, Mayumi Taniyama, Shinichiro Nakamura, Masayuki Uemura, Yoshitaka Takuma, Eiichiro Yumoto, Toshihiro Higashi, Takao Tsuji.   

Abstract

Insulin-like growth factor binding protein-3 (IGFBP-3) is postulated to be a mediator of growth suppression signals. Reduced expression of the IGFBP-3 was observed in nine out of 12 human hepatocellular carcinomas (HCC) (75%). Promoter hypermethylation of the IGFBP-3 was detected in four out of 12 HCCs (33%) although mutations were not identified. The expression of IGFBP-3 was restored by the demethylating agent 5-aza-2'-deoxycytidine in HCC cell line with promoter hypermethylation (HepG2). As IGFBP-3 functions like a tumor suppressor gene, it may be used as a therapeutic target for HCC.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11804742     DOI: 10.1016/s0304-3835(01)00736-4

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  43 in total

1.  Low expression of IGFBP-3 predicts poor prognosis in patients with esophageal squamous cell carcinoma.

Authors:  Lei Zhao; Li-Ru He; Rui Zhang; Mu-Yan Cai; Yi-Ji Liao; Dong Qian; Mian Xi; Yi-Xin Zeng; Dan Xie; Meng-Zhong Liu
Journal:  Med Oncol       Date:  2011-12-14       Impact factor: 3.064

2.  Functional modulation of IGF-binding protein-3 expression in melanoma.

Authors:  Altaf A Dar; Shahana Majid; Mehdi Nosrati; David de Semir; Scot Federman; Mohammed Kashani-Sabet
Journal:  J Invest Dermatol       Date:  2010-04-01       Impact factor: 8.551

Review 3.  Molecular classification and novel targets in hepatocellular carcinoma: recent advancements.

Authors:  Yujin Hoshida; Sara Toffanin; Anja Lachenmayer; Augusto Villanueva; Beatriz Minguez; Josep M Llovet
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

4.  Involvement of insulin-like growth factor-binding protein-3 in the effects of histone deacetylase inhibitor MS-275 in hepatoma cells.

Authors:  Wen Hui Lin; Janet L Martin; Deborah J Marsh; Michelle M Jack; Robert C Baxter
Journal:  J Biol Chem       Date:  2011-07-07       Impact factor: 5.157

5.  Activation of various downstream signaling molecules by IGFBP-3.

Authors:  Hanief Mohammad Shahjee; Nisan Bhattacharyya
Journal:  J Cancer Ther       Date:  2014-08-01

6.  Antitumor activity and immunogenicity of recombinant vaccinia virus expressing HPV 16 E7 protein SigE7LAMP is enhanced by high-level coexpression of IGFBP-3.

Authors:  J Musil; L Kutinova; K Zurkova; P Hainz; K Babiarova; J Krystofova; S Nemeckova
Journal:  Cancer Gene Ther       Date:  2014-02-21       Impact factor: 5.987

Review 7.  Cancer gene discovery in hepatocellular carcinoma.

Authors:  Lars Zender; Augusto Villanueva; Victoria Tovar; Daniela Sia; Derek Y Chiang; Josep M Llovet
Journal:  J Hepatol       Date:  2010-03-20       Impact factor: 25.083

Review 8.  Targeting insulin-like growth factor-I and insulin-like growth factor-binding protein-3 signaling pathways. A novel therapeutic approach for asthma.

Authors:  Hyun Lee; So Ri Kim; Youngman Oh; Seong Ho Cho; Robert P Schleimer; Yong Chul Lee
Journal:  Am J Respir Cell Mol Biol       Date:  2014-04       Impact factor: 6.914

9.  Serum IGFBP-3 is a more effective predictor than IGF-1 and IGF-2 for the development of hepatocellular carcinoma in patients with chronic HCV infection.

Authors:  Eiman Aleem; Ayman Elshayeb; Nihal Elhabachi; Amal Refaat Mansour; Ahmed Gowily; Asmaa Hela
Journal:  Oncol Lett       Date:  2011-12-30       Impact factor: 2.967

10.  Promoter methylation of IGFBP-3 and p53 expression in ovarian endometrioid carcinoma.

Authors:  Pao-Ling Torng; Ching-Wei Lin; Michael Wy Chan; Hui-Wen Yang; Su-Cheng Huang; Chin-Tarng Lin
Journal:  Mol Cancer       Date:  2009-12-11       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.